Ascendis Pharma A/S

ASND · NASDAQ

$243.37+$0.38 (+0.16%)TodayMarket closed ·
Prev close $242.99

About ASND

Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.

Employees
1,189
Headquarters
Hellerup
Listed
Jan 28, 2015
Sector
Health Care
Industry
Biotechnology

Leadership

Ascendis Pharma A/S executives
NameTitleSince
Albert Cha——
Jan Mikkelsen—2007
Scott Smith——
Lotte Soenderbjerg——
Michael Jensen—2008
Flemming Jensen——
Aimee Shu——
Stina Singel——
Kennett Sprogoee——
Donovan Wu——
Mads Bodenhoff——
Jethro Ekuta——
Sherrie Glass——
Lisa Bright——
William Fairey——
Lars Holtug——
Siham Imani——

Revenue by product and region

Fiscal year ended Dec 31, 2025: $720.13M total revenue

By region

  • UNITED STATES$546.39M75.9%
  • Europe [member]$120.95M16.8%
  • Rest of world [member]$52.80M7.3%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.